Effect of pharmacy management on turnaround time of 4-factor prothrombin complex concentrate

Langstraat, Eileen; Martinelli, Ashley; Spoelhof, Brian; Shah, Shailly

doi:10.2146/ajhp160698

Cited by 4 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was suggested that the active involvement of the EICU pharmacist from the patient's condition confirmation to the 4F-PCC administration in the immediate vicinity of IV intravenous the emergency physician in real-time greatly contributed. Similar to our study, studies in other countries have reported a decrease in time from prescription ordering to 4F-PCC administration owing to better pharmacy management and ED pharmacist's intervention [4,5].…”

Section: Discussionsupporting

confidence: 90%

“…4F-PCC must be administered as soon as possible because an early reduction in the prothrombin time-international normalized ratio (PT-INR) has been reported to reduce mortality due to major bleeding [2]. In recent years, there have been reports on the reduction of time to 4F-PCC administration [3][4][5][6][7]. However, in the emergency intensive care unit (EICU), during the time period between patient presentation to 4F-PCC administration, it is necessary to confirm medication histories, design the complicated prescription, and combine intravenous vitamin K but the optimal procedure for this remains unknown.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Emergency intensive care unit pharmacist’s intervention may reduce time to four-factor prothrombin complex concentrate administration: a retrospective study

Imanaka

Kuwabara

Ikeda

et al. 2020

J Pharm Health Care Sci

View full text Add to dashboard Cite

Background: Four-factor prothrombin complex concentrate (4F-PCC) must be administered as soon as possible, and in our emergency intensive care unit (EICU), pharmacists are available on weekdays for consultation on expediting 4F-PCC administration. Although recent reports have described a reduction in time to 4F-PCC administration, few studies have addressed if this is because of EICU pharmacist's intervention, and there are no such studies in Japan. Therefore, we aimed to examine whether EICU pharmacist's intervention reduced time to 4F-PCC administration. Methods: This single-center retrospective cohort study was conducted from December 2017 to May 2019. We enrolled patients who received 4F-PCC due to major bleeding or requirement of urgent surgical/invasive procedures (n = 10). Patients were divided into two groups, namely, the intervention group (n = 5), in which EICU pharmacists consulted on weekdays, and the nonintervention group (n = 5), in which an intervention was not possible because of the absence of the EICU pharmacist. Results: The median time from patient presentation to the EICU to 4F-PCC administration (103 min vs. 111 min, p = 0.4) was similar between the two groups; however, the median time from 4F-PCC prescription ordering to administration was significantly shorter in the intervention group than in the nonintervention group (21 min vs. 60 min, p = 0.02). Conclusions: EICU pharmacist's intervention improves the process from 4F-PCC prescription to administration and can reduce time to 4F-PCC administration.

show abstract

Section: Discussionsupporting

confidence: 90%